[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1287 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
H. RES. 1287

Of inquiry directing the President to provide certain documents in the 
President's possession to the House of Representatives relating to the 
   recall of infant formula manufactured by Abbott Laboratories and 
         potential impacts on the infant formula supply chain.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             July 26, 2022

 Mr. Walberg submitted the following resolution; which was referred to 
                  the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
Of inquiry directing the President to provide certain documents in the 
President's possession to the House of Representatives relating to the 
   recall of infant formula manufactured by Abbott Laboratories and 
         potential impacts on the infant formula supply chain.

    Resolved, That not later than 14 days after the adoption of this 
resolution, the President is directed to furnish to the House of 
Representatives copies of any document or record, audio recording, 
memorandum, call log, correspondence (electronic or otherwise), or 
other communication in the President's possession (or any portion 
thereof), that refers or relates to the following:
            (1) the memoranda and report referenced in the testimony 
        given by Dr. Robert Califf on May 25, 2022, during the hearing 
        related to the recall of infant formula manufactured by Abbott 
        Laboratories and potential impacts on the infant formula supply 
        chain held by the Committee on Subcommittee on Oversight and 
        Investigations of the Committee on Energy and Commerce of the 
        House of Representatives;
            (2) all communications between the Commissioner of Food and 
        Drugs and other staff of the Food and Drug Administration and 
        the White House regarding the infant formula recall and 
        potential impact during or before February 2022;
            (3) the failure of the Food and Drug Administration to 
        ensure the whistleblower complaint submitted to the Food and 
        Drug Administration by an employee of Abbott Laboratories was 
        sent to all necessary and appropriate officials and what 
        actions the Food and Drug Administration has taken to prevent 
        such a failure from happening in the future;
            (4) the number of full-time equivalent positions in the 
        Office of Regulatory Affairs of the Food and Drug 
        Administration that remain vacant for food safety compliance 
        and inspection staff;
            (5) all communications between the Food and Drug 
        Administration and the Department of Agriculture about the 
        recall of infant formula manufactured by Abbott Laboratories 
        and the potential impact on the Special Supplemental Nutrition 
        Program for Women, Infants, and Children, including the timing 
        of such communications; and
            (6) the number of submissions pending at the Food and Drug 
        Administration as of the date of the adoption of this 
        resolution for the marketing of infant formula, delineated by 
        domestic and foreign manufacturers.
                                 <all>